Conferences

Using A Modular Approach to Develop Oncolytic Cell Therapies

August 27th 2021

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

CD20-Targeted Gene Therapy

July 24th 2021

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.

Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors

July 22nd 2021

The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.

Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM

June 19th 2021

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

The Role of CAR NK Cells: Competition or Compliment to CAR T-Cell Therapy?

June 13th 2021

New studies into chimeric antigen receptor (CAR)–engineered natural killer (NK) cells has shown promising results, explained Ulrike Köhl, PhD, MD, professor of immune oncology and director of the Institute for Clinical Immunology at the University of Leipzig in Germany.

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

June 13th 2021

Long-term efficacy assessment of brexucabtagene autoleucel demonstrated high rates of MRD negativity and CR rates in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Speakers Suggest Moving Newer Agents Into Earlier Lines in MM

June 13th 2021

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.

Cilta-Cel Significantly Improved Response and Survival Over Conventional Therapy for R/R MM

June 12th 2021

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.

Pivotal Trials Address Pressing Questions With CAR T-Cell Therapy in B-Cell Lymphoma

April 22nd 2021

Nilanjan Ghosh MD, PhD, highlights progress made with CAR T-cell therapies in B-cell lymphoma and some ongoing trials generating interest in the field.